Clinical Trial Update: Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Preliminary safety, pharmacokinetic and efficacy signals for AC0010 in EGFR T790M–positive NSCLC from Phase 1/2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AC0010

Snippet

Sponsor: Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN